TSC-101 is an HA-2-specific TCR-T therapy candidate directed at eliminating white blood cells, including residual cancer cells, in HLA-A*02:01-positive patients undergoing standard-of-care HCT. HA-2 is a minor histocompatibility antigen that is present on all blood cells, malignant or benign. We believe that healthy donor T cells engineered to express an HA-2-specific TCR will generate an anti-cancer effect in patients, leading to a reduction in relapse rates post-HCT and an increase in long-term survival.

We are currently conducting a Phase 1 clinical study of TSC-101 in patients with AML, ALL, or MDS undergoing standard-of-care HCT. Eligible patients require transplant donors who do not have the HLA-A*02 allele. For more detailed information about our ongoing clinical study please visit: NCT05473910.

We are focusing on patients that are HLA-A*02:01-positive (as ~97% of patients that are A*02:01 positive are also HA-2-positive) who have donors that are HLA-A*02-negative. While the patient is undergoing HCT, the donor’s T cells are engineered with a TCR that recognizes HA-2. Following the transplant, we infuse the patient with the engineered donor-derived T cells. These TSC-101 cells target any residual cancer cells because the cancer cells are HA-2-positive, but won’t touch any of the new blood cells because they are derived from the donor and are HA-2-negative.

Expansion Opportunities

We plan to expand this program further with the addition of TCRs for additional HLA types. TSC-102-A0301 and TSC-102-A0101 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45. Like TSC-101, these candidates are designed to eliminate residual cancer cells and prevent relapse in patients undergoing HCT. TSC-102-A0301 and TSC-102-A0101 are designed for patients with HLA types A*03:01 and A*01:01, respectively.